We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Duodenal Stent Minimizes Small Intestine Cancer Symptoms

By HospiMedica International staff writers
Posted on 02 Nov 2011
An innovative controlled-release stent offers symptomatic relief of gastric outlet obstruction caused by gastrointestinal (GI) cancers in the duodenum. More...


The Evolution Duodenal controlled-release stent expands palliative care options for patients experiencing issues associated with malignant gastric outlet obstruction (GOO), a late stage complication of a variety of GI related cancers such as pancreatic, gastric, duodenal, and cholangiocarcinoma. The stent offers these patients a minimally invasive alternative to relieve symptoms and potentially life-threatening complications resulting from duodenal obstruction, such as abdominal pain, vomiting, malnutrition, and aspiration. The new stent allows for more precise placement and conforms to the patient’s duodenum to reduce the risk of migration, thanks to 18 crowns placed at both the distal and proximal ends, which allow the stent to adapt to the natural curvature of the anatomy.

The proximal and distal flanges are designed to reduce the risk of stent migration, while the patented Flexor catheter with kink-resistant technology provides tracking ability and maneuverability for deployment in the difficult anatomy of the duodenum. Controlled release and recapturing abilities are designed to provide physicians with precise control and maneuverability, ensuring proper placement and potentially reducing complications such as migration and perforation. The Evolution Duodenal stent is a product of Cook Medical (Bloomington, IN, USA) and has been approved by the US Food and Drug Administration (FDA).

“We’re excited to be expanding our line of Evolution stents by bringing to the US market a stent platform that aids physicians and has been available globally for several years,” said Barry Slowey, global business unit leader for Cook Medical’s Endoscopy division. “This stent has been used to treat thousands of patients around the globe, potentially improving quality of life for these patients, and hopefully minimizing the painful symptoms associated with this disease.”

“The Evolution duodenal stent includes several product features that are designed to make stent placement easier and more precise for the physician,” said Prof. John Lee, MD, of the University of California Irvine (UCI) Medical Center (USA). “These features of the stent allow for better wall apposition and potentially reduce the risk of migration, both of which are essential when treating patients with gastric outlet obstructions.”

Related Links:
Cook Medical
University of California Irvine (UCI) Medical Center


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Adjustable Mobile Barrier
M-458
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.